OUP Management Company’s Cartesian Therapeutics RNAC Stock Holding History

OUP Management Company’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$914K	Hold	28,751	–	–	2.06%	6
2023 Q2	$966K	Hold	28,751	–	–	1.65%	8
2023 Q1	$1.2M	Hold	28,751	–	–	2.39%	9
2022 Q4	$975K	Hold	28,751	–	–	1.59%	11
2022 Q3	$1.42M	Hold	28,751	–	–	2.2%	9
2022 Q2	$1.13M	Hold	28,751	–	–	1.56%	12
2022 Q1	$1.06M	Hold	28,751	–	–	0.81%	15
2021 Q4	$2.81M	Buy	+28,751	New	+$3.09M	1.27%	15

Other funds holding RNAC

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OUP Management Company's RNAC Position: Q3 2023 in Review

OUP Management Company held its Cartesian Therapeutics (RNAC) position steady in Q3 2023 at 28,751 shares worth $914K. The position accounts for 2.06% of the portfolio, ranked #6.

OUP Management Company first reported a position in RNAC in Q4 2021 and has held it in 8 quarters since. The position peaked at $2.81M in Q4 2021. 87 funds tracked by Wall St. Rank hold RNAC as of Q3 2023.

OUP Management Company held 28,751 shares of Cartesian Therapeutics worth $914K as of Q3 2023.
OUP Management Company left its Cartesian Therapeutics share count unchanged in Q3 2023.
Cartesian Therapeutics made up 2.06% of OUP Management Company's portfolio in Q3 2023, its #6 holding.
OUP Management Company first reported a position in Cartesian Therapeutics in Q4 2021 and has held it in 8 quarters since.
OUP Management Company's Cartesian Therapeutics position peaked at $2.81M in Q4 2021.
87 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2023.

Based on OUP Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.